Guardant Health, Inc. (GH)
NASDAQ: GH · IEX Real-Time Price · USD
27.10
-0.37 (-1.35%)
At close: May 31, 2024, 4:00 PM
27.15
+0.05 (0.18%)
After-hours: May 31, 2024, 7:23 PM EDT
Guardant Health Revenue
Guardant Health had revenue of $603.73M in the twelve months ending March 31, 2024, with 25.21% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $168.49M with 30.90% year-over-year growth. In the year 2023, Guardant Health had annual revenue of $563.95M with 25.45% growth.
Revenue (ttm)
$603.73M
Revenue Growth
+25.21%
P/S Ratio
5.49
Revenue / Employee
$339,362
Employees
1,779
Market Cap
3.32B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 563.95M | 114.41M | 25.45% |
Dec 31, 2022 | 449.54M | 75.89M | 20.31% |
Dec 31, 2021 | 373.65M | 86.92M | 30.32% |
Dec 31, 2020 | 286.73M | 72.36M | 33.75% |
Dec 31, 2019 | 214.38M | 123.74M | 136.52% |
Dec 31, 2018 | 90.64M | 40.80M | 81.85% |
Dec 31, 2017 | 49.84M | 24.59M | 97.40% |
Dec 31, 2016 | 25.25M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Envista Holdings | 2.56B |
Amedisys | 2.25B |
LivaNova | 1.19B |
Prestige Consumer Healthcare | 1.13B |
HUTCHMED (China) | 838.00M |
Tandem Diabetes Care | 770.01M |
Corcept Therapeutics | 523.53M |
Ultragenyx Pharmaceutical | 442.59M |
GH News
- 1 day ago - Guardant Health Named to TIME100 Most Influential Companies - Business Wire
- 2 days ago - Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening - Business Wire
- 9 days ago - FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option - Business Wire
- 9 days ago - U.S. FDA advisers back approval for Guardant's blood-based cancer test - Reuters
- 9 days ago - Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening - Business Wire
- 10 days ago - Guardant Health to Participate in Upcoming Investor Conferences - Business Wire
- 11 days ago - Trinity Industries, Inc. Announces Offering of Additional 7.750% Senior Notes Due 2028 - Business Wire
- 11 days ago - Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications - Business Wire